comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-11 07:59:15 - browse：13

A photograph of someone preparing small petri dishes, each holding several 1-7 day old embryos, for cells to be extracted from each embryo to test for viability at an in vitro fertilization lab — In vitro fertilization lab staff prepare small petri dishes, each holding embryos. (This sample image doesn't necessarily show embryos grown in media from CooperSurgical, a supply giant now facing lawsuits.) Michael Wyke/AP

Patients from all over the country are filing lawsuits against medical supply giant CooperSurgical, alleging that fluid the company sent to in vitro fertilization clinics destroyed their embryos.

The fluid, called culture media, is filled with nutrients that allow embryos to develop enough to ultimately be implanted into a uterus. CooperSurgical acknowledged that the batch of fluid may have stunted embryo growth in a product recall notice, but it hasn’t disclosed exactly what went wrong. Lawsuits claim the media lacked magnesium, a key nutrient, while a Cooper representative told STAT the cause is still under investigation.

The recall could be a one-off manufacturing fluke. But the debacle, and the uncertainty around the problems with the fluid, sheds light on a larger problem: IVF doctors rarely know the exact composition of culture media in the first place. The Food and Drug Administration asks manufacturers for a list of materials before the media goes on the market, an FDA spokesperson told STAT. Companies will sometimes give clinics this information voluntarily, along with required labeling information like mouse embryo data, instructions for use, and warnings. But the FDA doesn’t require companies to list the ingredients or their proportions publicly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Even great ERs can’t make up for American health disparities

entertainment

WSS

Biden administration opens offers in Medicare drug price negotiations

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Woodcock on FDA’s accelerated approval and her next chapter

Readout Newsletter: What happened with Sarepta's Duchenne data

Some dementia cases could be undiagnosed liver disease

Hospitals warn Medicare's drug payment fix is ‘unlawful’

explore

comprehensive

leisure time

Bright Health sells Medicare Advantage business to Molina

SAMSHA loosens regulations on methadone treatment centers

Dobbs anniversary: the lost opportunity of abortion as health care

FDA drug safety: Singulair case shows systemic surveillance flaws

Duchenne breakthrough therapy leaves behind pioneering families

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

State Dept. review finds Biden bears some blame for Afghanistan failures

The pink breast cancer awareness ribbon needs a redesign

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

knowledge

Biden administration opens offers in Medicare drug price negotiations

Physician subsidies by hospitals soar in wake of No Surprises Act

Emergency medicine has repudiated 'excited delirium.' Now what?

ARCH Venture Partners is raising $3 billion for a life sciences fund

Testing for cancer recurrence creates a new limbo for patients

Diversifying clinical trials isn't enough to close racial gaps: study

focus

leisure time

entertainment

knowledge